Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns.
Novo Nordisk stock rose Wednesday after the drugmaker reported quarterly earnings above analysts’ expectations, but forecast ...
News Highlights: Top Company News of the Day - Wednesday at 1 AM ET
Toyota Motor sold 10.8 million vehicles globally in 2024, retaining its position as the world's biggest carmaker. The Japanese automakers had announced a plan to combine in December. Novo's Wegovy and ...
NBC Connecticut1d
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...
Looking to buy weight-loss jabs? You need to pass more checks from now on
New industry rules require visual size checks or GP medical records for online fat jab purchases. The updated guidelines ensure weight-loss jabs like ...
Tougher rules on weight loss jabs after people with eating disorders get prescriptions
New checks on people wanting drugs such as Wegovy or Mounjaro will include verifying their body mass index in a video ...
Winnipeg Free Press6d
About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds
More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health condition ...